Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Filament Health Corp (OP: FLHLF ) 0.0373 +0.0023 (+6.57%) Streaming Delayed Price Updated: 12:05 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Filament Health Corp < Previous 1 2 3 Next > Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder March 15, 2023 Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions. Via Benzinga Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More February 27, 2023 Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and... Via Benzinga [Video] Revolutionizing Mental Health: Filament Health CEO Discusses The Future Of Psychedelic Medicine February 21, 2023 Cannabis enthusiasts and industry insiders alike will find the latest episode of Benzinga's Cannabis Insider show both informative and engaging. Via Benzinga Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More February 21, 2023 Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... Via Benzinga Supply Partnerships: Filament's Psilocybin Trial In Canada, PharmAla's MDMA Program In Australia February 14, 2023 Filament’s Psilocybin, Tested On Mild Cognitive Impairment By CAMH Via Benzinga EXCLUSIVE: Defining 'Natural' Psychedelics, State Regulations & Ayahuasca's Benefits January 26, 2023 (Part three of a three-part series) See previous stories: EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans Via Benzinga Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More January 25, 2023 Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First? Via Benzinga Jaguar Health Announces Establishment of Board of Directors for Newly Formed Joint Venture Magdalena Biosciences January 23, 2023 Via ACCESSWIRE Psychiatry And Business Collaborate: European Psychedelics Trial Tackles Alcohol Addiction January 20, 2023 Clinical-stage natural psychedelics developer Filament Health (OTCQB: FLHLF) and the Psychiatric Center Copenhagen’s collaborative clinical trial has been approved by the Danish Medicines Agency and is... Via Benzinga 6 Psychedelics Companies Take Action: Here Are The Latest, Major Announcements January 10, 2023 Second week of 2023, and business is up and running. Let’s take a look at the announcements shared by some of the companies in the psychedelics space. Via Benzinga Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses January 10, 2023 Via ACCESSWIRE Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More December 19, 2022 Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. Via Benzinga EXCLUSIVE: The Psychedelics Debate Is 'Raging' As Filament Debuts Ayahuasca Pill December 16, 2022 Part two of a three-part series. Previous story: Standardized Ayahuasca Pill Is Officially Here, Feast Yourself With The Exclusive Details & Insights Via Benzinga KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing December 16, 2022 Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire Psychedelics Company Filament Signs Licensing Deal With Psyence In US, UK And EU December 15, 2022 Filament Health Corp. (OTCQB: FLHLF) and Psyence Group Inc. (OTCQB: PSYGF) have inked a worldwide commercial licensing deal. Via Benzinga EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans December 15, 2022 Part one of a three-part series. The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. Via Benzinga KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th December 13, 2022 Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire Filament Health to Present Live at VirtualInvestorConferences.com December 15th December 13, 2022 Filament invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) Featured in Virtual Coverage of the KCSA Mental Health Investor Conference December 13, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project December 06, 2022 Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and... Via Benzinga Natural Psychedelics Extraction & Standardization Obtains Two New US Patents December 01, 2022 Clinical-stage psychedelics drug development company Filament Health Corp. Via Benzinga Psyched: Colorado Legalizes Psychedelics, NYC Treats Alcoholism With Ketamine, $30M Series A For Startup November 15, 2022 Colorado Voters Approve Initiative To Legalize And Regulate Psychedelics Via Benzinga Filament Health Shares Q3 2022 Results, On Road To Becoming Industry's Natural Psilocybin Supplier November 11, 2022 Clinical-stage natural psychedelic drug development company Filament Health Corp. (OTCQB: FLHLF) reported its third quarter financial results and operational highlights for the period ended September... Via Benzinga Psyched: Brock Pierce Joins Psychedelic VC, Colorado's Psychedelics Legalization, Zappy Zapolin's Open Letter & More November 07, 2022 Crypto Billionaire Brock Pierce Joins Psychedelic Venture Fund, Says 'Potential Reward Is Immeasurable' Via Benzinga EXCLUSIVE: Crypto Billionaire Brock Pierce Joins Psychedelic Venture Fund, Says 'Potential Reward Is Immeasurable' November 04, 2022 Brock Pierce, the crypto billionaire, economist and philanthropist serving as chairman of the Bitcoin Foundation, has joined Jeremy Gardner’s psychedelics-focused venture fund Mystic Ventures as a... Via Benzinga Filament Begins First Ever FDA-Approved Clinical Trial On Naturally-Derived Psychedelic Drugs July 08, 2022 Clinical-stage natural psychedelics company Filament Health Corp. Via Benzinga Filament Health Announces First Dosing in Groundbreaking FDA-Approved Psilocin Clinical Trial July 07, 2022 From Filament Health Corp. Via Business Wire Canadian Special Access Program Further Authorizes Novel Psychedelic Drugs For Emergency Treatments June 16, 2022 For those unaware, Canada provides a legal way for patients presenting unresolved mental health issues to receive psychedelic-assisted treatment. Via Benzinga Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill June 15, 2022 Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider. Via Benzinga Two Psychedelics Drug Development Companies Work To Produce Novel Plant-Based Compounds For Mental Health Disorders June 09, 2022 Filament Health Corp. (OTCQB: FLHLF) and Jaguar Health, Inc. (NASDAQ: JAGX) have signed a letter of intent for a collaboration agreement. Via Benzinga < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.